Misplaced Pages

Fletikumab

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Monoclonal antibody Pharmaceutical compound
Fletikumab
Monoclonal antibody
Type?
TargetIL20
Clinical data
Other namesNNC0109-0012
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC6494H10000N1728O2050S44
Molar mass146492.12 g·mol

Fletikumab (NNC0109-0012) (INN) is a monoclonal antibody designed for the treatment of rheumatoid arthritis that targets IL-20.

This drug was being developed by Novo Nordisk A/S until Novo ceased work in inflammation.

References

  1. World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 110" (PDF). WHO Drug Information. 27 (4).
  2. Statement On A Nonproprietary Name Adopted By The USAN Council - Fletikumab, American Medical Association.
  3. Kragstrup TW, Andersen T, Heftdal LD, Hvid M, Gerwien J, Sivakumar P, Taylor PC, Senolt L, Deleuran B (2018). "The IL-20 Cytokine Family in Rheumatoid Arthritis and Spondyloarthritis". Frontiers in Immunology. 9: 2226. doi:10.3389/fimmu.2018.02226. PMC 6167463. PMID 30319661.
Interleukin receptor modulators
IL-1
IL-2
IL-3
IL-4
IL-5
IL-6
IL-7
IL-8
  • See CXCR1 (IL-8Rα) and CXCR2 (IL-8Rβ) here instead.
IL-9
IL-10
IL-11
IL-12
IL-13
IL-15
IL-17
IL-18
IL-20
IL-21
IL-22
IL-23
IL-27
IL-28
IL-31
IL1RL1
IL1RL2
Others
JAK
Others


Stub icon

This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it.

Categories:
Fletikumab Add topic